{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"3.5","upperLimit":"8.0","value":"7.0"},{"groupId":"OG004","lowerLimit":"6.5","upperLimit":"35.8","value":"27.7"},{"groupId":"OG005","lowerLimit":"4.6","upperLimit":"9.9","value":"7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"39"}],"units":"Participants"}],"description":"Kaplan-Meier curves will be generated for PFS stratified by histology; median PFS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG000","title":"Phase I, All Histologies, Lenalidomide 15 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG001","title":"Phase I, All Histologies, Lenalidomide 20 mg"},{"description":"Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG002","title":"Phase I, All Histologies, Lenalidomide 25 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG003","title":"Phase II, Diffuse Large B-Cell Subtype"},{"description":"Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG004","title":"Phase II, Follicular Subtype"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG005","title":"Phase II, Lymphoma NOS"}],"paramType":"MEDIAN","populationDescription":"Note: Only phase II patients were followed for progression-free survival.","reportingStatus":"POSTED","timeFrame":"Time from study entry until disease progression or death from any cause, assessed up to 5 years","title":"Progression-free Survival (PFS) (Phase II)","type":"SECONDARY","unitOfMeasure":"Months"}